Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Alexander K ConverseWaisman Center, University of Wisconsin-Madison Madison, Wisconsin 53705 akconverse@wisc.edu.ORCID 0000-0002-2035-9331
Maryann N KraskoDepartment of Communication Science and Disorders, University of Wisconsin-Madison Madison, Wisconsin 53706.
Denis Michael RudischDepartment of Communication Science and Disorders, University of Wisconsin-Madison Madison, Wisconsin 53706.
Maxim S SlesarevWaisman Center, University of Wisconsin-Madison Madison, Wisconsin 53705.
John C SzotDepartment of Communication Science and Disorders, University of Wisconsin-Madison Madison, Wisconsin 53706.
Catherine L GallagherDepartment of Neurology, University of Wisconsin-Madison; William S. Middleton VA Hospital Madison, Wisconsin 53705.
Michelle R CiucciDepartment of Communication Science and Disorders, University of Wisconsin-Madison Madison, Wisconsin 53706.ORCID 0000-0002-9913-8784
Funding
Waisman Center Intellectual and Developmental Disabilities Research CenterP50HD105353 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Brittany Gail Travers · 2021 to 2026
$8.5M
Preclinical trial for dysarthria treatment in Parkinson diseaseR01DC018584 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI CIUCCI, MICHELLE RENEE · 2021 to 2025
$3.3M
Vocal dysfunction and vagally mediated brainstem pathology in prodromal Parkinson diseaseF31DC022161 · NIDCD · UNIVERSITY OF WISCONSIN-MADISON · PI KRASKO, MARYANN N · 2024 to 2024
Evidence suggests that the neurotransmitter norepinephrine may play an important role in Parkinson disease (PD). The norepinephrine transporter (NET) regulates noradrenergic signaling and can serve as an index of noradrenergic innervation in neuroimaging studies. The
Indexed as
BrainNeuroimagingNorepinephrine Plasma Membrane Transport ProteinsParkinson DiseasePositron-Emission TomographyProtein KinasesAnimalsDisease Models, AnimalFemaleFluorine RadioisotopesLigandsMalePTEN-Induced Putative KinaseRadiopharmaceuticalsRatsRats, Long-EvansFluorine RadioisotopesLigandsNorepinephrine Plasma Membrane Transport ProteinsProtein KinasesPTEN-Induced Putative KinaseRadiopharmaceuticals[18F]NS12137noradrenalinenorepinephrine transporterParkinson’s diseasePink1-/- ratprelimbic area
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Positron Emission Tomography (PET) Neuroimaging of the · full record | Socratic